The Do No Harm in Medicaid Act amends title XIX of the Social Security Act to bar Federal Medical Assistance Percentage (FMAP) payments for a defined category of “specified gender transition procedures” when furnished to individuals under 18 who are enrolled in a State Medicaid plan or a waiver of such a plan. The bill inserts a new paragraph into section 1903(i) to withhold federal matching for those services and adds a new subsection 1905(kk) that lists covered surgeries, implants, and drug therapies and provides narrow exceptions.
This is a funding‑level restriction: it does not criminalize care, nor does it directly change private‑insurance rules, but it removes federal Medicaid support for a broad set of gender‑affirming medical services for minors. That shift affects state budget choices, provider reimbursement, and access to care for Medicaid‑enrolled youth while raising practical questions about definitions, clinical exceptions, and federal enforcement.
At a Glance
What It Does
The bill amends 42 U.S.C. 1396b(i) to add a new paragraph denying federal Medicaid matching funds for 'specified gender transition procedures' furnished to individuals under 18, and it adds 42 U.S.C. 1396d(kk) defining those procedures (a long enumerated list of surgeries, implants, and medicines) plus limited exceptions.
Who It Affects
State Medicaid programs and their budgets, hospitals and clinics that provide gender‑affirming services to minors, pediatric endocrinologists and surgeons, Medicaid managed care plans, and Medicaid‑enrolled minors and their families seeking those services.
Why It Matters
Withholding federal match changes the financial calculus for states: they can either stop covering these services or pay them entirely with state funds. The bill also creates definitional and operational challenges for CMS, state agencies, and clinicians when determining what qualifies as a prohibited procedure or an authorized exception.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
At its core, the bill operates through the federal Medicaid matching mechanism. It tells states that if they pay for certain listed procedures, drugs, or administrative expenses for Medicaid enrollees under 18 that are characterized as 'specified gender transition procedures,' the federal government will not provide FMAP for those expenditures.
The practical effect is financial: the federal share is withdrawn rather than directly ordering states to change their benefit packages.
The bill supplies a long, specific statutory catalogue of covered items. That catalogue ranges from major reconstructive surgeries (phalloplasty, vaginoplasty, hysterectomy, mastectomy) through smaller plastics (facial feminizing/masculinizing procedures) to implants and buttock augmentation.
It also covers pharmaceuticals when used 'for the purpose of intentionally changing the body,' explicitly calling out puberty‑blocking agents (GnRH analogues) and cross‑sex hormones (testosterone, estrogen, progestogens) at doses described as 'supraphysiologic.'Exceptions are limited and conditional. The statute exempts puberty‑suppressing drugs when prescribed to treat medically verified precocious puberty and a set of treatments and procedures that are medically necessary to correct a verifiable disorder of sex development (DSD) or to treat infection, disease, injury, or life‑threatening conditions.
The exceptions require parental or guardian consent when the services are furnished to a minor. The bill also authorizes reconstructive procedures to restore anatomy to correspond with the individual’s sex after prior procedures.Finally, the bill provides a statutory definition of 'sex' grounded in reproductive anatomy and function—describing 'female' and 'male' in terms of bodies that produce eggs or sperm, while recognizing developmental or genetic anomalies as exceptions.
That definitional choice will drive eligibility determinations and likely be central to administrative guidance and litigation over what counts as a ‘specified’ procedure or a qualifying DSD.
The Five Things You Need to Know
The bill adds paragraph (28) to 42 U.S.C. §1396b(i), denying federal Medicaid matching funds for 'specified gender transition procedures' furnished to Medicaid enrollees under age 18, including state plan and waiver expenditures and related administrative costs.
The statute lists dozens of surgeries by name (e.g.
mastectomy, phalloplasty, vaginoplasty, orchiectomy, hysterectomy, metoidioplasty, chondrolaryngoplasty, penectomy) and covers 'plastic, cosmetic, or aesthetic surgery' that feminizes or masculinizes features.
It prohibits federal payment for placement of chest, erection, testicular, or gluteal implants and for administering or supplying puberty blockers (GnRH analogues) and cross‑sex hormones when used to intentionally change the body.
The bill carves out exceptions for (1) puberty blockers prescribed for clinically diagnosed precocious puberty and (2) medically necessary treatments for verifiable disorders of sex development, plus emergency or reconstructive procedures—but exceptions require parental or guardian consent.
The statute defines 'sex' in biological terms (ability to produce, transport, and utilize eggs or sperm), with allowances for developmental/genetic anomalies—language that will shape coverage determinations and clinical classifications.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
A one‑line provision naming the measure the 'Do No Harm in Medicaid Act.' This is purely stylistic but signals the bill’s stated policy frame; it has no operative legal effect on Medicaid administration.
Denial of FMAP for specified services for minors
This amendment inserts a new paragraph (28) into the federal statute that governs when the government will provide matching payments (FMAP) to states. The paragraph targets 'amounts expended for specified gender procedures under section 1905(kk) to an individual under 18 years of age enrolled in a State plan (or waiver),' and explicitly includes administrative expenditures tied to programs furnishing those services. Operationally, that means CMS would be directed to deny FMAP for such line‑item claims or to recoup federal share if it determines expenditures fall within the prohibition.
Definition of 'specified gender transition procedures' and exceptions
This is the substantive core. The new subsection (kk) provides a detailed list of surgeries, implants, and drug therapies treated as 'specified gender transition procedures' when performed to change an individual’s body so it 'no longer correspond[s] to the individual's sex.' Subparagraph (A) enumerates non‑exhaustive categories; subparagraph (B) sets out narrow exceptions (precocious puberty treatment; medically necessary care for disorders of sex development; treatment for infection/disease/injury resulting from prior procedures; and reconstructive restoration after prior procedures). Subparagraph (B) also conditions exceptions on parental or guardian consent when furnished to a minor.
Biological definition of sex used for coverage decisions
The statute defines 'male' and 'female' in biological terms tied to reproductive anatomy and gamete production, with an explicit carve‑out for developmental or genetic anomalies. Because the funding prohibition applies when procedures change the body 'to no longer correspond to the individual's sex,' the statutory sex definitions will be the touchstone for determining whether a procedure is targeted under the prohibition and whether an individual falls into an exception for DSD.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State officials who prefer to restrict Medicaid coverage: States can remove federal matching payments and thereby limit federal exposure, making it administratively and politically simpler to curtail coverage of the listed services for minors.
- State treasuries that choose to stop covering these services: If a state terminates coverage, it avoids matching obligations and potential future claims tied to these services.
- Payers and employers outside Medicaid that do not face federal matching rules: The bill focuses on Medicaid; private insurers are unaffected directly, which may advantage payers who already exclude such services.
Who Bears the Cost
- Medicaid‑enrolled transgender and gender‑diverse minors and their families: Federal funding withdrawal will reduce or eliminate Medicaid‑covered access to listed surgeries, implants, and hormone treatments for those under 18, shifting cost and access burdens to families or state budgets.
- Health care providers and clinics offering gender‑affirming care to minors: Hospitals, surgical centers, and specialty clinics will face lost Medicaid revenue for services that fall within the statutory list unless states continue coverage with non‑federal funds.
- States that maintain coverage: States that continue to provide these services for minors must finance them entirely with state dollars (no FMAP), increasing state budgetary pressure and potentially forcing benefit trade‑offs elsewhere.
- Medicaid managed care plans and contract administrators: Plans will need to update provider networks, prior authorization rules, capitation models, and reporting to reflect services no longer eligible for FMAP and to manage potential disputes and appeals.
Key Issues
The Core Tension
The bill pits two legitimate objectives against one another: protecting minors by restricting federal subsidy for interventions some find premature, versus preserving medical judgment, individualized care, and consistent access for Medicaid‑enrolled youth—especially those with clinically complex conditions—while respecting state discretion. Using funding withdrawal as the enforcement tool resolves one problem (federal fiscal exposure) but shifts hard choices to states, clinicians, and families without offering clear operational rules for the clinical and administrative gray areas it creates.
The bill operates through the FMAP lever, which changes incentives but does not itself ban states from using state funds to continue coverage. That creates a pragmatic trade‑off: states that want to maintain access can do so, but at full state cost, which will produce divergent coverage across states and raise equity issues for beneficiaries who move or cross state lines.
The statute’s long enumerated list reduces ambiguity in some respects, but it raises several operational questions: how will CMS and states determine whether a clinician performed a procedure 'for the purpose of intentionally changing the body'? What documentation will satisfy that test?
How will claims for multi‑component procedures be parsed when only part of a procedure is listed? The law also sweeps in administrative costs, which broadens enforcement to health‑plan operations and program administration rather than narrowly targeting discrete clinical bills.
The exceptions are narrow but hinge on clinical thresholds and consenting adults/parents. The DSD carve‑out requires 'medically verifiable' conditions and physician testing; that invites disputes about who qualifies, what tests suffice, and whether the same clinical pathway used by gender‑affirming teams could be treated as DSD care.
The parental‑consent requirement for exceptions is explicit, but the statute does not set out procedural rules for documenting consent or resolving disagreements between parents and minors or between parents and providers. Finally, the statutory definition of sex is biologically framed and will be decisive in coverage disputes—but it is phrased in a way that does not neatly map onto contemporary clinical diagnoses, leaving room for administrative interpretation, legal challenge, and inconsistent application across states and providers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.